Literature DB >> 8943868

Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders.

D K Miles1, M H Freedman, K Stephens, M Pallavicini, E L Sievers, M Weaver, T Grunberger, P Thompson, K M Shannon.   

Abstract

Children with neurofibromatosis type 1 (NF1) are at increased risk of developing malignant myeloid disorders, particularly juvenile chronic myelogenous leukemia/juvenile myelomonocytic leukemia (JCML/JMML). We investigated bone marrows from 11 such patients (8 boys and 3 girls) and detected allelic losses at the NF1 locus in 4 of them and probable losses in 2 others. To determine which hematopoietic cell lineages were derived from the abnormal clones, Epstein-Barr virus (EBV)-transformed cell lines and CD34+ cells were analyzed from 3 children with JCML with allelic losses in unfractionated marrow. CD34 cells from these 3 patients lacked the normal NF1 allele, whereas EBV cell lines retained it. Erythroblasts plucked from the burst-forming unit-erythroid colonies of one of these children lacked the normal NF1 allele. We also studied a 10-month-old boy with NF1 who developed an unusual myeloproliferative syndrome. His bone marrow and EBV cell line both showed loss of the normal NF1 allele. In our series and in the literature, male sex and maternal transmission of NF1 were associated with the highest risk of myeloid leukemia. These data (1) provide strong genetic evidence that NF1 functions as a tumor-suppressor in early myelopoiesis, (2) confirm the clonal nature of JCML/JMML, (3) suggest that the elevation in fetal hemoglobin seen in JCML/JMML is a result of primary involvement of erythroid progenitors in the malignant clone, (4) show consistent loss of NF1 in the CD34 cells of affected children and show that the malignant clone may also give rise to pre-B cells in some cases, and (5) implicate epigenetic factors in the development of leukemia in children with NF1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943868

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Lethal proliferation of erythroid precursors in a neonate with a germline PTPN11 mutation.

Authors:  Christian Peter Kratz; Michaela Nathrath; Peter Freisinger; Petra Dressel; Hans-Peter Assmuss; Cornelia Klein; Ayami Yoshimi; Stefan Burdach; Charlotte Marie Niemeyer
Journal:  Eur J Pediatr       Date:  2005-12-21       Impact factor: 3.183

Review 2.  Translational hematology.

Authors:  Klaus Geissler
Journal:  Wien Med Wochenschr       Date:  2014-09-10

3.  Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models.

Authors:  David K Meyerholz; Georgina K Ofori-Amanfo; Mariah R Leidinger; J Adam Goeken; Rajesh Khanna; Jessica C Sieren; Benjamin W Darbro; Dawn E Quelle; Jill M Weimer
Journal:  J Histochem Cytochem       Date:  2017-08-28       Impact factor: 2.479

Review 4.  Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Authors:  Shivani Ahlawat; Jaishri O Blakeley; Shannon Langmead; Allan J Belzberg; Laura M Fayad
Journal:  Skeletal Radiol       Date:  2019-08-08       Impact factor: 2.199

5.  Quantitative effects of Nf1 inactivation on in vivo hematopoiesis.

Authors:  Y Zhang; B R Taylor; K Shannon; D W Clapp
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

6.  Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies.

Authors:  Karen Stephens; Molly Weaver; Kathleen A Leppig; Kyoko Maruyama; Peter D Emanuel; Michelle M Le Beau; Kevin M Shannon
Journal:  Blood       Date:  2006-05-11       Impact factor: 22.113

7.  High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

Authors:  Jeffrey W Tyner; Heidi Erickson; Michael W N Deininger; Stephanie G Willis; Christopher A Eide; Ross L Levine; Michael C Heinrich; Norbert Gattermann; D Gary Gilliland; Brian J Druker; Marc M Loriaux
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

8.  Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.

Authors:  Mignon L Loh; Debbie S Sakai; Christian Flotho; Michelle Kang; Manfred Fliegauf; Sophie Archambeault; Charles G Mullighan; Leslie Chen; Eva Bergstraesser; Carlos E Bueso-Ramos; Peter D Emanuel; Henrik Hasle; Jean-Pierre Issa; Marry M van den Heuvel-Eibrink; Franco Locatelli; Jan Stary; Monica Trebo; Marcin Wlodarski; Marco Zecca; Kevin M Shannon; Charlotte M Niemeyer
Journal:  Blood       Date:  2009-07-01       Impact factor: 22.113

9.  An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Nicholas C P Cross; Eric Padron; Ramon V Tiu; Michael Savona; Luca Malcovati; Raoul Tibes; Rami S Komrokji; Jean-Jacques Kiladjian; Guillermo Garcia-Manero; Attilio Orazi; Ruben Mesa; Jaroslaw P Maciejewski; Pierre Fenaux; Raphael Itzykson; Ghulam Mufti; Eric Solary; Alan F List
Journal:  Haematologica       Date:  2015-09       Impact factor: 9.941

10.  Oncogenic Kras initiates leukemia in hematopoietic stem cells.

Authors:  Amit J Sabnis; Laurene S Cheung; Monique Dail; Hio Chung Kang; Marianne Santaguida; Michelle L Hermiston; Emmanuelle Passegué; Kevin Shannon; Benjamin S Braun
Journal:  PLoS Biol       Date:  2009-03-17       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.